tetano
Editor, Senior Moderator
J Am Heart Assoc
. 2021 Mar 16;10(6):e019636.
doi: 10.1161/JAHA.120.019636. Epub 2021 Mar 13.
Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis
Siva H Yedlapati[SUP] 1 [/SUP], Safi U Khan[SUP] 2 [/SUP], Swapna Talluri[SUP] 3 [/SUP], Ahmed N Lone[SUP] 1 [/SUP], Muhammad Zia Khan[SUP] 1 [/SUP], Muhammad Shahzeb Khan[SUP] 4 [/SUP], Ann M Navar[SUP] 5 [/SUP], Martha Gulati[SUP] 6 [/SUP], Heather Johnson[SUP] 7 [/SUP], Seth Baum[SUP] 8 [/SUP], Erin D Michos[SUP] 9 [/SUP]
Affiliations
Abstract
Background Influenza infection causes considerable morbidity and mortality in patients with cardiovascular disease. We assessed the effects of the influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease. Methods and Results We searched PubMed, Embase, and the Cochrane Library through January 2020 for randomized controlled trials and observational studies assessing the effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease. Estimates were reported as random effects risk ratios (RRs) with 95% CIs. Analyses were stratified by study design into randomized controlled trials and observational studies. A total of 16 studies (n=237 058), including 4 randomized controlled trials (n=1667) and 12 observational studies (n=235 391), were identified. Participants' mean age was 69.2?7.01 years, 36.6% were women, 65.1% had hypertension, 31.1% had diabetes mellitus, and 23.4% were smokers. At a median follow-up duration of 19.5 months, influenza vaccine was associated with a lower risk of all-cause mortality (RR, 0.75; 95% CI, 0.60-0.93 [P=0.01]), cardiovascular mortality (RR, 0.82; 95% CI, 0.80-0.84 [P<0.001]), and major adverse cardiovascular events (RR, 0.87; 95% CI, 0.80-0.94 [P<0.001]) compared with control. The use of the influenza vaccine was not associated with a statistically significant reduction of myocardial infarction (RR, 0.73; 95% CI, 0.49-1.09 [P=0.12]) compared with control. Conclusions Data from both randomized controlled trials and observational studies support the use of the influenza vaccine in adults with cardiovascular disease to reduce mortality and cardiovascular events, as currently supported by clinical guidelines. Clinicians and health systems should continue to promote the influenza vaccine as part of comprehensive secondary prevention.
Keywords: cardiovascular disease; influenza vaccine; meta?analysis; mortality.
. 2021 Mar 16;10(6):e019636.
doi: 10.1161/JAHA.120.019636. Epub 2021 Mar 13.
Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis
Siva H Yedlapati[SUP] 1 [/SUP], Safi U Khan[SUP] 2 [/SUP], Swapna Talluri[SUP] 3 [/SUP], Ahmed N Lone[SUP] 1 [/SUP], Muhammad Zia Khan[SUP] 1 [/SUP], Muhammad Shahzeb Khan[SUP] 4 [/SUP], Ann M Navar[SUP] 5 [/SUP], Martha Gulati[SUP] 6 [/SUP], Heather Johnson[SUP] 7 [/SUP], Seth Baum[SUP] 8 [/SUP], Erin D Michos[SUP] 9 [/SUP]
Affiliations
- PMID: 33719496
- DOI: 10.1161/JAHA.120.019636
Abstract
Background Influenza infection causes considerable morbidity and mortality in patients with cardiovascular disease. We assessed the effects of the influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease. Methods and Results We searched PubMed, Embase, and the Cochrane Library through January 2020 for randomized controlled trials and observational studies assessing the effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease. Estimates were reported as random effects risk ratios (RRs) with 95% CIs. Analyses were stratified by study design into randomized controlled trials and observational studies. A total of 16 studies (n=237 058), including 4 randomized controlled trials (n=1667) and 12 observational studies (n=235 391), were identified. Participants' mean age was 69.2?7.01 years, 36.6% were women, 65.1% had hypertension, 31.1% had diabetes mellitus, and 23.4% were smokers. At a median follow-up duration of 19.5 months, influenza vaccine was associated with a lower risk of all-cause mortality (RR, 0.75; 95% CI, 0.60-0.93 [P=0.01]), cardiovascular mortality (RR, 0.82; 95% CI, 0.80-0.84 [P<0.001]), and major adverse cardiovascular events (RR, 0.87; 95% CI, 0.80-0.94 [P<0.001]) compared with control. The use of the influenza vaccine was not associated with a statistically significant reduction of myocardial infarction (RR, 0.73; 95% CI, 0.49-1.09 [P=0.12]) compared with control. Conclusions Data from both randomized controlled trials and observational studies support the use of the influenza vaccine in adults with cardiovascular disease to reduce mortality and cardiovascular events, as currently supported by clinical guidelines. Clinicians and health systems should continue to promote the influenza vaccine as part of comprehensive secondary prevention.
Keywords: cardiovascular disease; influenza vaccine; meta?analysis; mortality.